MX2014014710A - Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar). - Google Patents
Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar).Info
- Publication number
- MX2014014710A MX2014014710A MX2014014710A MX2014014710A MX2014014710A MX 2014014710 A MX2014014710 A MX 2014014710A MX 2014014710 A MX2014014710 A MX 2014014710A MX 2014014710 A MX2014014710 A MX 2014014710A MX 2014014710 A MX2014014710 A MX 2014014710A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- alkyltriazole
- lpar antagonists
- lpar
- antagonists
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261661961P | 2012-06-20 | 2012-06-20 | |
| PCT/EP2013/062461 WO2013189864A1 (en) | 2012-06-20 | 2013-06-17 | N-alkyltriazole compounds as lpar antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014014710A true MX2014014710A (es) | 2015-03-04 |
Family
ID=48628667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014014710A MX2014014710A (es) | 2012-06-20 | 2013-06-17 | Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar). |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9321738B2 (instruction) |
| EP (1) | EP2864300A1 (instruction) |
| JP (1) | JP2015520202A (instruction) |
| KR (1) | KR20150021057A (instruction) |
| CN (1) | CN104411692A (instruction) |
| AU (1) | AU2013279512A1 (instruction) |
| BR (1) | BR112014030685A2 (instruction) |
| CA (1) | CA2869541A1 (instruction) |
| CL (1) | CL2014003243A1 (instruction) |
| CO (1) | CO7131358A2 (instruction) |
| CR (1) | CR20140525A (instruction) |
| EA (1) | EA201492285A1 (instruction) |
| HK (1) | HK1206342A1 (instruction) |
| IL (1) | IL236088A0 (instruction) |
| IN (1) | IN2014DN09348A (instruction) |
| MA (1) | MA37764A1 (instruction) |
| MX (1) | MX2014014710A (instruction) |
| PE (1) | PE20142448A1 (instruction) |
| PH (1) | PH12014502789A1 (instruction) |
| SG (1) | SG11201407220YA (instruction) |
| UA (1) | UA109868C2 (instruction) |
| WO (1) | WO2013189864A1 (instruction) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12014500355A1 (en) | 2011-08-15 | 2014-03-31 | Intermune Inc | Lysophosphatidic acid receptor antagonists |
| PE20142305A1 (es) * | 2012-06-20 | 2015-01-16 | Hoffmann La Roche | Compuestos de n-ariltriazol como antagonistas de lpar |
| PT2988743T (pt) | 2013-03-15 | 2021-03-03 | Epigen Biosciences Inc | Compostos heterocíclicos úteis no tratamento da doença |
| CA2953472C (en) | 2014-06-27 | 2022-08-02 | Ube Industries, Ltd. | Halogen-substituted heterocyclic compound salt |
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| CA3085347A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| ES2925626T3 (es) * | 2017-12-19 | 2022-10-19 | Bristol Myers Squibb Co | Acidos isoxazol-O-carbamoilciclohexílicos como antagonistas de LPA |
| CN112041304B (zh) | 2017-12-19 | 2025-03-07 | 百时美施贵宝公司 | 作为lpa拮抗剂的异噁唑n-连接的氨基甲酰基环己基酸 |
| ES2944304T3 (es) * | 2017-12-19 | 2023-06-20 | Bristol Myers Squibb Co | Pirazol azinas de ácido ciclohexílico como antagonistas de LPA |
| HRP20211918T8 (hr) * | 2017-12-19 | 2022-04-15 | Bristol-Myers Squibb Company | Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti |
| EP3728209A1 (en) * | 2017-12-19 | 2020-10-28 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azines as lpa antagonists |
| EP3728224B1 (en) | 2017-12-19 | 2023-01-11 | Bristol-Myers Squibb Company | Cyclohexyl acid triazole azoles as lpa antagonists |
| JP7256807B2 (ja) * | 2017-12-19 | 2023-04-12 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアゾール |
| WO2019126103A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azoles as lpa antagonists |
| EP3728223B1 (en) | 2017-12-19 | 2022-12-28 | Bristol-Myers Squibb Company | Cyclohexyl acid triazole azines as lpa antagonists |
| JP7202383B2 (ja) | 2017-12-19 | 2023-01-11 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのピラゾールｏ－架橋カルバモイルシクロヘキシル酸 |
| CN117126152A (zh) * | 2017-12-29 | 2023-11-28 | 生物马林药物股份有限公司 | 用于疾病治疗的乙醇酸氧化酶抑制剂 |
| JP7412424B2 (ja) * | 2018-09-18 | 2024-01-12 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのオキサビシクロ酸 |
| KR102800284B1 (ko) * | 2018-09-18 | 2025-04-23 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헵틸 산 |
| CN113473985A (zh) * | 2018-09-18 | 2021-10-01 | 百时美施贵宝公司 | 作为lpa拮抗剂的环戊酸 |
| EP4058144A1 (en) | 2019-11-15 | 2022-09-21 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof |
| CN115867556B (zh) | 2020-06-03 | 2025-05-06 | 吉利德科学公司 | Lpa受体拮抗剂及其用途 |
| TWI838626B (zh) | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| US11980609B2 (en) | 2021-05-11 | 2024-05-14 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| CN117295724A (zh) * | 2021-05-13 | 2023-12-26 | 吉利德科学公司 | Lpa受体拮抗剂及其用途 |
| CN118541360A (zh) | 2021-12-08 | 2024-08-23 | 吉利德科学公司 | Lpa受体拮抗剂及其用途 |
| TW202342017A (zh) | 2022-02-25 | 2023-11-01 | 美商洛子峰生物有限公司 | 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
| GB2466121B (en) * | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) * | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| US20110065695A1 (en) | 2009-09-11 | 2011-03-17 | Jeremy Beauchamp | Use of aminodihydrothiazines for the treatment or prevention of diabetes |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| WO2011159550A2 (en) * | 2010-06-14 | 2011-12-22 | Amidra Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonist and uses thereof |
| WO2011159633A1 (en) * | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Inhalable formulations of lysophosphatdic acid receptor antagonists |
| AU2011338561A1 (en) * | 2010-12-07 | 2013-07-25 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis |
| WO2012138648A1 (en) | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| PH12014500355A1 (en) | 2011-08-15 | 2014-03-31 | Intermune Inc | Lysophosphatidic acid receptor antagonists |
-
2013
- 2013-06-17 IN IN9348DEN2014 patent/IN2014DN09348A/en unknown
- 2013-06-17 CA CA2869541A patent/CA2869541A1/en not_active Abandoned
- 2013-06-17 EP EP13729330.4A patent/EP2864300A1/en not_active Withdrawn
- 2013-06-17 UA UAA201500428A patent/UA109868C2/ru unknown
- 2013-06-17 PE PE2014002232A patent/PE20142448A1/es not_active Application Discontinuation
- 2013-06-17 MX MX2014014710A patent/MX2014014710A/es unknown
- 2013-06-17 SG SG11201407220YA patent/SG11201407220YA/en unknown
- 2013-06-17 WO PCT/EP2013/062461 patent/WO2013189864A1/en not_active Ceased
- 2013-06-17 EA EA201492285A patent/EA201492285A1/ru unknown
- 2013-06-17 US US14/401,009 patent/US9321738B2/en not_active Expired - Fee Related
- 2013-06-17 JP JP2015517704A patent/JP2015520202A/ja not_active Ceased
- 2013-06-17 AU AU2013279512A patent/AU2013279512A1/en not_active Abandoned
- 2013-06-17 MA MA37764A patent/MA37764A1/fr unknown
- 2013-06-17 HK HK15106927.8A patent/HK1206342A1/xx unknown
- 2013-06-17 KR KR1020147035768A patent/KR20150021057A/ko not_active Ceased
- 2013-06-17 CN CN201380032285.0A patent/CN104411692A/zh active Pending
- 2013-06-17 BR BR112014030685A patent/BR112014030685A2/pt not_active Application Discontinuation
-
2014
- 2014-11-17 CR CR20140525A patent/CR20140525A/es unknown
- 2014-11-21 CO CO14256136A patent/CO7131358A2/es unknown
- 2014-11-28 CL CL2014003243A patent/CL2014003243A1/es unknown
- 2014-12-04 IL IL236088A patent/IL236088A0/en unknown
- 2014-12-15 PH PH12014502789A patent/PH12014502789A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201492285A1 (ru) | 2015-04-30 |
| JP2015520202A (ja) | 2015-07-16 |
| HK1206342A1 (en) | 2016-01-08 |
| UA109868C2 (ru) | 2015-10-12 |
| AU2013279512A1 (en) | 2014-10-16 |
| IL236088A0 (en) | 2015-02-01 |
| CR20140525A (es) | 2015-01-12 |
| PE20142448A1 (es) | 2015-01-28 |
| PH12014502789A1 (en) | 2015-02-09 |
| CN104411692A (zh) | 2015-03-11 |
| US9321738B2 (en) | 2016-04-26 |
| KR20150021057A (ko) | 2015-02-27 |
| EP2864300A1 (en) | 2015-04-29 |
| IN2014DN09348A (instruction) | 2015-07-17 |
| BR112014030685A2 (pt) | 2017-06-27 |
| CA2869541A1 (en) | 2013-12-27 |
| WO2013189864A1 (en) | 2013-12-27 |
| MA37764A1 (fr) | 2016-01-29 |
| CL2014003243A1 (es) | 2015-03-20 |
| US20150133511A1 (en) | 2015-05-14 |
| SG11201407220YA (en) | 2014-12-30 |
| CO7131358A2 (es) | 2014-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502363A1 (en) | N-aryltriazole compounds as lpar antagonists | |
| PH12014502789A1 (en) | N-alkyltriazole compounds as lpar antagonists | |
| PH12014502364A1 (en) | Substituted pyrazole compounds as lpar antagonists | |
| WO2014179564A8 (en) | Thiazolopyrrolidine inhibitors of ror-gamma | |
| IN2014DN09434A (instruction) | ||
| IN2014MN02598A (instruction) | ||
| WO2014028589A3 (en) | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
| MX354102B (es) | Derivados de bencimidazol-prolina. | |
| IN2015DN01119A (instruction) | ||
| EA201591195A1 (ru) | Новые хинолоновые производные | |
| MX2016002794A (es) | Compuestos antiproliferativos. | |
| PH12013500007A1 (en) | Piperidine derivatives and their use for the treatment of metabolic disorders | |
| PH12014501967B1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
| IN2014DN06869A (instruction) | ||
| UA117154C2 (uk) | Антагоністи s1p3 | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| MX2015001657A (es) | Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar). | |
| WO2014160143A3 (en) | Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders | |
| WO2015002755A3 (en) | Compounds for the treatment of malaria | |
| PH12015502717B1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| PH12017501736B1 (en) | Indole derivatives | |
| MY166057A (en) | Carbocyclic nucleosides and their pharmaceutical use and compositions | |
| CA2905957C (en) | Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders | |
| UA112586C2 (uk) | Похідні бензімідазолпроліну |